The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis - Wikidata - awgldk - TriplyDB

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

http://www.wikidata.org/entity/Q34858352

about

Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis [Intracellular targets : current data on effectiveness and safety profile].Significant association between TAP2 polymorphisms and rheumatoid arthritis: a meta-analysis.Association of NQO1 and TNF polymorphisms with Parkinson's disease: A meta-analysis of 15 genetic association studies Meta-analyses of 10 polymorphisms associated with the risk of schizophrenia.Update on Janus kinase antagonists in inflammatory bowel disease.Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis.Association between LGALS2 3279C>T and coronary artery disease: A case-control study and a meta-analysis.Meta-analyses of seven GIGYF2 polymorphisms with Parkinson's disease Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.Polymorphisms of DRD2 and DRD3 genes and Parkinson's disease: A meta-analysis.Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.New treatments for inflammatory rheumatic disease.Treatment in juvenile rheumatoid arthritis and new treatment options.Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib.Survey on management strategies of rheumatoid arthritis in Saudi Arabia: a Saudi Society for Rheumatology Initiative.Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway.The role of the JAK/STAT signal pathway in rheumatoid arthritis.

P2860

Q26772850-68828643-3270-47FF-BEB1-31B60511BCAB Q27330386-1F94AE58-1AA2-4704-AA18-92639BE066B0 Q28066559-342CC7CF-1E2A-4958-9BC2-227C91C9109F Q30689247-FEFC42E6-F7B4-4773-A057-C22939D0B804 Q33876125-9A1236D4-4CCB-418B-8ADF-55E1E9383E3F Q33932167-5E0417DD-CA79-4DD2-960F-A0F7E1BE58D6 Q33932502-03EB7C24-563A-4C25-A83A-73040EC0FB22 Q34030650-06005A10-D286-4F6F-9DC2-B304A96E74F3 Q34047746-AD725E9B-B69F-4E07-B885-4F4CA37AFB5A Q34265297-E84E5DCB-81C8-499F-9CFE-5801DF347107 Q34265447-1CC5CD1D-114B-4630-A5C4-D3B04611A920 Q35754101-A143517D-55DC-4804-8702-FBE3733C8278 Q37567704-A81577EA-0843-4245-B3F2-0BC949A4CBBF Q37706850-B1DFC6D4-F1A2-486F-9D0C-733D9C430801 Q38181051-BF6ADE9E-453E-4491-B1CD-ADF52266CDB7 Q38203622-E1285130-9EB2-48CE-A036-59A869A99787 Q38266252-CF3B5550-A103-4EBD-A17D-8889027CA33C Q38528889-95B39850-EF9F-4808-A721-7E063452A15F Q38604390-320E8FAE-62F9-401C-8A59-EC956D6DD901 Q38965691-9DD2F473-7D3C-44B3-8BE3-3B97301FCE2E Q50910994-D5BEFA26-22F1-4A7A-AAD1-B41BC73AA70A Q55027042-D10677E8-38E5-49CB-ABDE-E14DB2533FE4 Q55487787-742A7C82-3465-4E0B-9524-7F9543771C8B

P2860

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

http://www.wikidata.org/entity/Q34858352

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

The effectiveness of tofacitin ...... matic review and meta-analysis

@ast

The effectiveness of tofacitin ...... matic review and meta-analysis

@en

The effectiveness of tofacitin ...... matic review and meta-analysis

@nl

type

label

The effectiveness of tofacitin ...... matic review and meta-analysis

@ast

The effectiveness of tofacitin ...... matic review and meta-analysis

@en

The effectiveness of tofacitin ...... matic review and meta-analysis

@nl

prefLabel

The effectiveness of tofacitin ...... matic review and meta-analysis

@ast

The effectiveness of tofacitin ...... matic review and meta-analysis

@en

The effectiveness of tofacitin ...... matic review and meta-analysis

@nl

P1433

Q34858352-57F89DEC-C17B-4596-9497-F6204B9B8622

P1476

Q34858352-5D71356B-234B-4DDD-9A5B-F7AB630DBBBC

P2093

Q34858352-1853FED9-D88E-4A35-9DC6-5E024EDE6B5B

Q34858352-636C0E83-0E78-411A-ABE9-5B24E7A5C544

Q34858352-BEACD73B-569F-4116-9A87-80F39D88EE2F

P2860

Q34858352-1248882D-2AEF-4783-974E-2DE938CAD024

Q34858352-29ADC043-950E-419E-AF3F-BB9D44BABB31

Q34858352-30D07F65-DE79-4153-BDC8-11F3DD948169

Q34858352-31CDD56E-1AD2-435A-833A-A3C40570A9D4

Q34858352-3A089ADE-C9CB-4BA1-8A3E-9CE088BED1B5

Q34858352-454C5197-3AB3-4E8B-ACE5-6FA7CFF1DAA0

Q34858352-45C134F6-49B9-4646-9EB9-C0A14BD8EBA2

Q34858352-4C03D29D-B35A-4145-968D-175EA2AD1AFE

Q34858352-72AEEB9F-6401-4748-9BF4-8378B8B35C43

Q34858352-79C76704-189A-4503-856A-664DFD4334A4

P304

Q34858352-BF1869C4-1460-47E4-8066-A518F5D60256

P31

Q34858352-1DB0FC8F-E9FD-4B2F-A528-FA73E51E634F

Q34858352-1bca2f99-40a1-4649-8605-8fc1a3bd4f71

Q34858352-65654869-2DD0-4603-899C-7F4EE748651A

P356

Q34858352-361E0FF1-03F2-4767-A569-98A4C91D4FC4

P433

Q34858352-B8A5812C-14BF-47AC-B126-577AE56EDD4C

P478

Q34858352-4CA10EBA-D772-4164-896D-B534CF1B4FF3

P50

Q34858352-6A716C61-DA6E-4489-BACF-5902467F203B

P577

Q34858352-25F581AF-57DA-4D2D-9EBF-C1230F73E180

Q34858352-80A2CEA4-0009-4D72-83D7-7D184C4CE3FC

P5875

Q34858352-4563827D-EFA9-4288-8A00-D50819FB0274

P698

Q34858352-BD3A260C-7BEC-450E-BDCA-5B5FF7C1859B

P921

Q34858352-40B102E5-3BC9-4BF4-B274-651C2BB22A8E

Q34858352-65BBDC45-8280-4891-80EA-DB2F2E101819

Q34858352-868BBD21-9E37-4F11-9D53-8006972F8EC7

Q34858352-8929858B-88B6-41CE-8EF1-EABD1515CE21

Q34858352-C4F9CC77-DA0C-4802-92C3-D36676827D41

P932

Q34858352-57E9602A-58E5-4150-BDF7-C3236DFCEEE5

P356

S10067-013-2329-9

P1433

Clinical Rheumatology

P1476

The effectiveness of tofacitin ...... matic review and meta-analysis

@en

P2093

Alicja Mikrut

http://www.w3.org/2001/XMLSchema#string

Natalia Wiśniewska

http://www.w3.org/2001/XMLSchema#string

Paweł Kawalec

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.

Tofacitinib for the treatment of rheumatoid arthritis.

Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

P304

1415-1424

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10067-013-2329-9

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

251234925

http://www.w3.org/2001/XMLSchema#string

P698

23877486

http://www.w3.org/2001/XMLSchema#string

P921

rheumatoid arthritis

heterocyclic compound

mechanism of action

P932

3778229

http://www.w3.org/2001/XMLSchema#string